Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
immunoPET Imaging Probes for Breast Cancer
NCT06715826Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]F-RESCA-RT4 and [18F]F-RESCA-RB14 in breast cancer, sponsored by Renji Hospital. Primary endpoints: Biodistribution of [18F]F-RESCA-RT4/ [18F]F-RESCA-RB14 at 1 day, Standardized uptake value at 1 day and 4 more. Started Sep 2024; status: recruiting.
02
Drugs
[18F]F-RESCA-RT4[18F]F-RESCA-RB14
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06715826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715826.